Advertisement

Soft-Tissue Tumors and Tumorlike Conditions

  • Yong-Whee BahkEmail author
Chapter

Abstract

Soft-tissue tumors are defined as neoplasms derived from nonepithelial extraskeletal tissue of the body excluding the reticuloendothelial system, neuroglial cells, and supporting tissue of various parenchymal organs (Enzinger and Weiss, Soft tissue tumors, St. Louis, Mosby:1–13, 1983). Representative soft tissues from which neoplasms commonly arise are the muscles, fat, skin, blood and lymph vessels, lymph nodes, and nerve fibers. A survey of 1331 consecutive cases of benign soft-tissue tumors showed lipoma to be the most common, accounting for nearly half of the entire series, and fibrocystic tumors and hemangioma were relatively common (Myhre-Jensen, Acta Orthop Scand 52:287–293, 1981). Among sarcomas, liposarcoma ranked first, and fibrosarcoma, rhabdomyosarcoma, unclassified sarcomas, leiomyosarcoma, and synovial sarcoma followed in decreasing order. The prevalence rate of sarcoma was estimated to be approximately 1% of all malignant tumors, and the benign to malignant mesenchymal tumor ratio was 100:1 in a hospital population (Enzinger and Weiss, Soft tissue tumors, St. Louis, Mosby:1–13, 1983).

References

  1. Anvar MD, Khiabani HZ, Nesland JM et al (2000) Vascular and stromal features in the skin of the lower limb in patients with chronic limb ischemia (CLI) and oedema. Eur J Vasc Endovasc Surg 20:125–131CrossRefPubMedGoogle Scholar
  2. Beres RA, Patel N, Krasnow AZ et al (1991) Concentration of Tc-99 m MDP in ovarian carcinoma and its soft tissue metastases. Clin Nucl Med 16:550–552CrossRefPubMedGoogle Scholar
  3. Burke W, Rubens MB (1993) Uptake of technetium-99 m methylene diphosphonate by a pulmonary hamartoma/mesenchymoma. Br J Radiol 66:74–76CrossRefPubMedGoogle Scholar
  4. Cory DA, Siddiqui AR, Cohen MD (1987) Uptake of technetium 99 m MDP by hepatoblastoma. Eur J Nucl Med 12:546–547CrossRefPubMedGoogle Scholar
  5. Desai AG, Schaffer B, Park CH (1983) Accumulation of bone-scanning agents in hepatoma. Radiology 149:292CrossRefPubMedGoogle Scholar
  6. Enzinger FM, Weiss SW (1983) General considerations. In: Soft tissue tumors. Mosby, St. Louis, pp 1–13Google Scholar
  7. Garty I, Rosen G, Risescu J (1984) Extraosseous 99mTc-MDP uptake in mediastinal thyroid goiter: two case reports. Eur J Nucl Med 9:521–524CrossRefPubMedGoogle Scholar
  8. McKenna D, Igbal A, O’Keeffe D (2004) Tc-99 m methylene diphosphonate uptake in a primary lung cancer. Clin Nucl Med 29:723–724CrossRefGoogle Scholar
  9. Montes TC, Munoz C, Rivero JI et al (1999) Uptake of Tc-99 m sestamibi and Tc-99 m MDP in anaplastic carcinoma of the thyroid (nondiagnostic CT and ultrasound scans). Clin Nucl Med 24:355–356CrossRefPubMedGoogle Scholar
  10. Murphy MD, Fairbairn KJ, Parman LM et al (1995) From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiographic-pathology correlation. Radiographics 15:893–917CrossRefGoogle Scholar
  11. Myhre-Jensen O (1981) A consecutive 7-year series of 1331 benign tissue tumours. Clinicopathologic data. Comparison with sarcomas. Acta Orthop Scand 52:287–293CrossRefPubMedGoogle Scholar
  12. Piccolo S, Lastoria S, Muto P et al (1997) Scintimammography with 99mTc-MDP in the detection of primary breast cancer. Q J Nucl Med 41:225–230PubMedGoogle Scholar
  13. Pickhardt PJ, McDermott M (1997) Intense uptake of technetium-99 m-MDP in primary breast adenocarcinoma with sarcomatoid metaplasia. J Nucl Med 38:528–530PubMedGoogle Scholar
  14. Riedy G, Adler L (2000) Tc-99 m MDP thyroid uptake in a patient with a large nontoxic goiter. Clin Nucl Med 25:929–930CrossRefPubMedGoogle Scholar
  15. Rohren EM (2001) Tc-99 m MDP uptake in a calcified bladder tumor. Clin Nucl Med 26:58–59CrossRefPubMedGoogle Scholar
  16. Romyn AM, Bushnell DL, Freeman ML, Kaplan E (1987) Visualization of metastatic liver disease on technetium-99 m bone scintigraphy. Clin Nucl Med 12:264–267CrossRefPubMedGoogle Scholar
  17. Shih WJ, Deland FH, Domstad PA, Purcell M (1986) Ring-like uptake pattern of a skeletal imaging agent in a huge renal cell carcinoma. Clin Nucl Med 11:319–321CrossRefPubMedGoogle Scholar
  18. Silberstein EB, Francis MD, Tofe AJ, Slough CL (1975) Distribution of 99mTc-Sn diphosphonate and free 99mTc-pertechnetate in selected hard and soft tissues. J Nucl Med 16:58–61PubMedGoogle Scholar
  19. Teixeira AB, Etchebehere CS, Calvalho, et al. (2000) Tc-99m MDP uptake in uterine leiomyoma. Clin Nucl Med 25(6):484Google Scholar
  20. Wahner HW, Dewanjee MK (1981) Drug-induced modulation of Tc-99 m pyrophosphate tissue distribution: what is involved? J Nucl Med 22:555–559PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and RadiologySun Ae General HospitalSeoulSouth Korea

Personalised recommendations